"Immunotoxins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
| Descriptor ID |
D000922
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.450 D12.776.377.715.548.114.580.450 D27.888.569.271
|
| Concept/Terms |
Immunotoxins- Immunotoxins
- Cytotoxin-Antibody Conjugates
- Conjugates, Cytotoxin-Antibody
- Cytotoxin Antibody Conjugates
- Immunotoxin
- Antibody-Toxin Hybrids
- Antibody Toxin Hybrids
- Hybrids, Antibody-Toxin
- Affinotoxins
- Antibody-Toxin Conjugates
- Antibody Toxin Conjugates
- Conjugates, Antibody-Toxin
- Toxin-Antibody Conjugates
- Conjugates, Toxin-Antibody
- Toxin Antibody Conjugates
- Toxin-Antibody Hybrids
- Hybrids, Toxin-Antibody
- Toxin Antibody Hybrids
- Monoclonal Antibody-Toxin Conjugates
- Antibody-Toxin Conjugates, Monoclonal
- Conjugates, Monoclonal Antibody-Toxin
- Monoclonal Antibody Toxin Conjugates
Toxins, Chimeric- Toxins, Chimeric
- Chimeric Toxins
- Toxin Conjugates
- Conjugates, Toxin
- Toxin Carriers
- Carriers, Toxin
- Toxin Conjugate
- Conjugate, Toxin
- Chimeric Toxin
- Toxin, Chimeric
- Toxin Carrier
- Carrier, Toxin
|
Below are MeSH descriptors whose meaning is more general than "Immunotoxins".
Below are MeSH descriptors whose meaning is more specific than "Immunotoxins".
This graph shows the total number of publications written about "Immunotoxins" by people in this website by year, and whether "Immunotoxins" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 5 | 0 | 5 |
| 1998 | 7 | 5 | 12 |
| 1999 | 5 | 1 | 6 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 0 | 4 |
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 7 | 10 |
| 2004 | 2 | 1 | 3 |
| 2005 | 3 | 3 | 6 |
| 2006 | 4 | 3 | 7 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 3 | 2 | 5 |
| 2010 | 3 | 0 | 3 |
| 2011 | 8 | 1 | 9 |
| 2012 | 5 | 1 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 1 | 4 |
Below are the most recent publications written about "Immunotoxins" by people in Profiles.
-
Microcystin-Induced Immunotoxicity in Fishes: A Scoping Review. Toxins (Basel). 2021 10 29; 13(11).
-
Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A. 2021 07 20; 118(29).
-
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 05 13; 137(19):2634-2645.
-
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 07 15; 27(14):3916-3925.
-
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 01; 68(1):e28574.
-
A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Int J Cancer. 2020 01 15; 146(2):449-460.
-
Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. CNS Oncol. 2019 11 01; 8(3):CNS38.
-
Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins (Basel). 2018 05 21; 10(5).
-
Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies. AIDS Res Hum Retroviruses. 2017 Nov; 33(S1):S70-S80.
-
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 10 05; 130(14):1620-1627.